Update on testicular germ cell tumors

Current Opinion in Oncology

Volumn 23, Issue 3, 2011, Pages 265-270

  Mannuel, Heather D ^a,b,c   Mitikiri, Nirupama ^a   Hussain, Arif ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

chemotherapy; genetic studies; germ cell tumor; nonseminomatous germ cell tumor; platinum refractory disease; salvage therapy; seminoma; surveillance; survivorship

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; VINBLASTINE;

CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; GENE AMPLIFICATION; GENETIC ANALYSIS; GERM CELL TUMOR; HUMAN; MOLECULAR GENETICS; MORBIDITY; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TESTIS TUMOR;

FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 79955009381     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834579f0     Document Type: Review

References (12)

1. Diamantopoulos N, Kortsaris A. Testicular germ cell tumors. J BUON 2010; 15:421-434.
2. Duran I, García-Velasco A, Ballestín C, et al. Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clin Transl Oncol 2010; 12:443-449.
3. Wermann H, Stoop H, Gillis AJ, et al. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol 2010; 221:433-442.
4. Turnbull C, Rapley EA, Seal S, et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet 2010;42:604-607.
5. Ulisse S, Baldini E, Mottolese M, et al. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. BMC Cancer 2010; 10:151.
6. Tandstad T, Dahl O, Cohn-Cedarmark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENO- TECA management program. J Clin Oncol 2009; 27:2122-2128.
7. Westermann DH, Schefer H,Thalmann GN, et al. Long-term follow up results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage 1 nonseminomatous germ cell tumors of the testis. J Urol 2008; 179:163-166. (Pubitemid 350216759)
8. Mannuel H, Hussain A. Update on testicular germ cell tumors. Curr Opin Oncol 2010; 22:236-241.
9. Pagliaro L. Testicular cancer: when less is more. Curr Oncol Rep 2010; 12:271-277
10. Feldman D, Sheinfeld J, Bajorin D, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28:1706-1713.
11. Haugnes H, Aass N, Fossa S, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18:241-248. (Pubitemid 46323088)
12. Travis L, Beard C, Allan J, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010; 102:1114-1130.